NASDAQ:UPI - Uroplasty Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.22 0.00 (0.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.22
Today's RangeN/A
52-Week Range$1.05 - $4.05
Average Volume124,964 shs
Market Capitalization$27.68 million
P/E RatioN/A
Dividend YieldN/A

About Uroplasty (NASDAQ:UPI)

Uroplasty logoCogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive UPI News and Ratings via Email

Sign-up to receive the latest news and ratings for UPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-31.58%
Return on Equity-87.33%
Return on Assets-60.82%


Outstanding Shares22,150,000

Uroplasty (NASDAQ:UPI) Frequently Asked Questions

What is Uroplasty's stock symbol?

Uroplasty trades on the NASDAQ under the ticker symbol "UPI."

How were Uroplasty's earnings last quarter?

Uroplasty, Inc. (NASDAQ:UPI) posted its quarterly earnings data on Thursday, January, 22nd. The medical device company reported ($0.06) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.02. The medical device company earned $6.67 million during the quarter, compared to analyst estimates of $6.89 million. Uroplasty had a negative return on equity of 87.33% and a negative net margin of 31.58%. View Uroplasty's Earnings History.

Has Uroplasty been receiving favorable news coverage?

News coverage about UPI stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Uroplasty earned a media sentiment score of 0.11 on Accern's scale. They also gave media headlines about the medical device company an impact score of 45.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Uroplasty?

Shares of UPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Uroplasty's stock price today?

One share of UPI stock can currently be purchased for approximately $1.22.

How big of a company is Uroplasty?

Uroplasty has a market capitalization of $27.68 million.

How can I contact Uroplasty?

Uroplasty's mailing address is 5420 Feltl Road, MINNETONKA, MN 55343, United States. The medical device company can be reached via phone at +1-952-4266140.

MarketBeat Community Rating for Uroplasty (UPI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Uroplasty and other stocks. Vote "Outperform" if you believe UPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Uroplasty (NASDAQ:UPI) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/26/2016 forward)


Uroplasty (NASDAQ:UPI) Earnings History and Estimates Chart

Earnings by Quarter for Uroplasty (NASDAQ:UPI)

Uroplasty (NASDAQ UPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/22/2015Q3($0.04)($0.06)$6.89 million$6.67 millionViewListenView Earnings Details
10/23/2014Q2($0.07)($0.05)$6.49 million$6.46 millionViewListenView Earnings Details
7/24/2014Q1($0.05)($0.10)$6.35 million$6.39 millionViewListenView Earnings Details
5/15/2014Q4 13($0.04)($0.05)$6.40 million$6.36 millionViewN/AView Earnings Details
1/23/2014Q314($0.04)($0.03)$6.13 million$6.40 millionViewListenView Earnings Details
10/24/2013Q214($0.05)($0.04)$6.09 million$6.00 millionViewListenView Earnings Details
8/1/2013Q1 2014($0.05)($0.08)$5.60 million$5.84 millionViewN/AView Earnings Details
5/30/2013Q4 2013($0.04)($0.05)$5.59 million$5.54 millionViewListenView Earnings Details
1/24/2013Q3 2013($0.04)($0.02)ViewN/AView Earnings Details
10/25/2012Q2 2013($0.05)($0.03)ViewN/AView Earnings Details
7/26/2012Q1 2013($0.04)($0.05)ViewN/AView Earnings Details
5/24/2012Q4 2012($0.07)($0.03)ViewN/AView Earnings Details
1/26/2012Q3 2012($0.08)($0.05)ViewN/AView Earnings Details
10/27/2011Q2 2012($0.08)($0.06)ViewN/AView Earnings Details
7/28/2011Q1 2012($0.07)($0.06)ViewN/AView Earnings Details
5/25/2011Q4 2011($0.07)($0.06)ViewN/AView Earnings Details
1/27/2011Q3 2011($0.07)($0.07)ViewN/AView Earnings Details
10/27/2010Q2 2011($0.07)($0.05)ViewN/AView Earnings Details
8/10/2010Q1 2011($0.06)ViewN/AView Earnings Details
5/27/2010Q4 2010($0.04)ViewN/AView Earnings Details
2/1/2010Q3 2010($0.03)ViewN/AView Earnings Details
11/2/2009Q2 2010($0.06)ViewN/AView Earnings Details
8/3/2009Q1 2010($0.09)ViewN/AView Earnings Details
6/4/2009Q4 2009($0.11)ViewN/AView Earnings Details
2/3/2009Q3 2009($0.06)ViewN/AView Earnings Details
10/29/2008Q2 2009($0.04)ViewN/AView Earnings Details
7/31/2008Q1 2009($0.03)ViewN/AView Earnings Details
6/3/2008Q4 2008($0.05)ViewN/AView Earnings Details
2/11/2008Q3 2008($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Uroplasty (NASDAQ:UPI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Uroplasty (NASDAQ UPI) Insider Trading and Institutional Ownership History

Insider Trading History for Uroplasty (NASDAQ:UPI)

Uroplasty (NASDAQ UPI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2015Brett ReynoldsCFOBuy5,000$1.32$6,600.00View SEC Filing  
1/29/2015Kevin H RocheDirectorBuy50,000$1.23$61,500.00View SEC Filing  
1/29/2015Robert KillCEOBuy25,000$1.26$31,500.00View SEC Filing  
7/30/2014Kevin H RocheDirectorBuy10,000$2.45$24,500.00View SEC Filing  
7/29/2014Kevin H RocheDirectorBuy9,000$2.44$21,960.00View SEC Filing  
6/3/2014Kevin H RocheDirectorBuy10,000$2.97$29,700.00View SEC Filing  
6/2/2014Robert KillCEOBuy13,950$2.95$41,152.50View SEC Filing  
3/6/2014Susan Hartjes HolmanVPSell38,000$3.98$151,240.00274,680View SEC Filing  
1/29/2014Susan Hartjes HolmanSVPSell52,500$4.59$240,975.00312,680View SEC Filing  
12/11/2013Robert Patrick MaxwellDirectorSell3,819$2.70$10,311.30136,584View SEC Filing  
8/23/2013Brett ReynoldsCFOBuy8,000$2.99$23,920.0058,000View SEC Filing  
8/23/2013James StaunerDirectorBuy8,300$3.03$25,149.0035,450View SEC Filing  
8/7/2013Robert KillCEOBuy36,050$2.77$99,858.50346,050View SEC Filing  
8/6/2013Darin HammersVPBuy6,800$2.82$19,176.006,800View SEC Filing  
(Data available from 1/1/2013 forward)


Uroplasty (NASDAQ UPI) News Headlines

Critical Analysis: Uroplasty (UPI) vs. ConforMIS (CFMS)Critical Analysis: Uroplasty (UPI) vs. ConforMIS (CFMS) - February 25 at 5:20 AM
Critical Survey: Uroplasty (UPI) versus Amedica (AMDA)Critical Survey: Uroplasty (UPI) versus Amedica (AMDA) - February 24 at 3:02 PM
RTI Surgical (RTIX) versus Uroplasty (UPI) Financial ReviewRTI Surgical (RTIX) versus Uroplasty (UPI) Financial Review - February 21 at 5:06 AM
Critical Analysis: Cerus (CERS) vs. Uroplasty (UPI)Critical Analysis: Cerus (CERS) vs. Uroplasty (UPI) - February 1 at 11:43 AM
Contrasting Obalon Therapeutics (OBLN) and Uroplasty (UPI)Contrasting Obalon Therapeutics (OBLN) and Uroplasty (UPI) - January 3 at 5:36 PM
Comparing Uroplasty (UPI) and Endologix (ELGX)Comparing Uroplasty (UPI) and Endologix (ELGX) - January 3 at 5:34 AM
Smith & Nephew SNATS (SNN) versus Uroplasty (UPI) Financial ReviewSmith & Nephew SNATS (SNN) versus Uroplasty (UPI) Financial Review - December 18 at 8:18 AM
Analyzing Smith & Nephew SNATS (SNN) & Uroplasty (UPI)Analyzing Smith & Nephew SNATS (SNN) & Uroplasty (UPI) - December 16 at 5:10 PM
Analyzing Second Sight Medical Products (EYES) & Uroplasty (UPI)Analyzing Second Sight Medical Products (EYES) & Uroplasty (UPI) - December 13 at 9:18 PM
Uroplasty (UPI) vs. The Competition Financial ComparisonUroplasty (UPI) vs. The Competition Financial Comparison - December 13 at 5:38 PM
Head to Head Analysis: Uroplasty (UPI) vs. Glaukos (GKOS)Head to Head Analysis: Uroplasty (UPI) vs. Glaukos (GKOS) - December 13 at 3:54 PM
Uroplasty (UPI) and The Competition Head-To-Head SurveyUroplasty (UPI) and The Competition Head-To-Head Survey - December 13 at 1:34 PM
Head to Head Analysis: Uroplasty (UPI) and Its PeersHead to Head Analysis: Uroplasty (UPI) and Its Peers - December 12 at 5:16 PM
Head to Head Survey: Uroplasty (UPI) vs. Its RivalsHead to Head Survey: Uroplasty (UPI) vs. Its Rivals - December 11 at 9:30 PM
Reviewing Uroplasty (UPI) and The CompetitionReviewing Uroplasty (UPI) and The Competition - December 10 at 5:22 PM
Head to Head Analysis: Uroplasty (UPI) & Its CompetitorsHead to Head Analysis: Uroplasty (UPI) & Its Competitors - December 10 at 3:30 PM
Comparing Uroplasty (UPI) & The CompetitionComparing Uroplasty (UPI) & The Competition - December 10 at 12:14 PM
Contrasting Uroplasty (UPI) and The CompetitionContrasting Uroplasty (UPI) and The Competition - December 9 at 7:18 PM
Uroplasty (UPI) and Its Peers Head-To-Head ContrastUroplasty (UPI) and Its Peers Head-To-Head Contrast - December 9 at 5:30 AM
Financial Review: Uroplasty (UPI) & The CompetitionFinancial Review: Uroplasty (UPI) & The Competition - December 9 at 5:30 AM
Uroplasty (UPI) and The Competition Financial ReviewUroplasty (UPI) and The Competition Financial Review - December 7 at 7:28 PM
Uroplasty (UPI) vs. Its Peers Critical AnalysisUroplasty (UPI) vs. Its Peers Critical Analysis - December 7 at 9:24 AM
Head to Head Comparison: Uroplasty (UPI) & Its RivalsHead to Head Comparison: Uroplasty (UPI) & Its Rivals - December 6 at 5:30 PM
Critical Survey: Uroplasty (UPI) and The CompetitionCritical Survey: Uroplasty (UPI) and The Competition - December 6 at 3:12 AM
Reviewing Uroplasty (UPI) and Its PeersReviewing Uroplasty (UPI) and Its Peers - December 5 at 5:26 PM
Uroplasty (UPI) vs. The Competition Financial ReviewUroplasty (UPI) vs. The Competition Financial Review - December 5 at 5:28 AM
Uroplasty (UPI) & Its Peers Critical ContrastUroplasty (UPI) & Its Peers Critical Contrast - December 4 at 1:28 PM
Contrasting Uroplasty (UPI) & Its PeersContrasting Uroplasty (UPI) & Its Peers - December 4 at 8:44 AM
Financial Analysis: St Jude Medical (STJ) vs. Uroplasty (UPI)Financial Analysis: St Jude Medical (STJ) vs. Uroplasty (UPI) - December 3 at 1:24 AM
Uroplasty (UPI) versus Its Rivals Critical ReviewUroplasty (UPI) versus Its Rivals Critical Review - November 30 at 7:26 PM
Uroplasty (UPI) vs. Its Peers Head to Head ContrastUroplasty (UPI) vs. Its Peers Head to Head Contrast - November 29 at 11:32 PM
Comparing Uroplasty (UPI) and Its PeersComparing Uroplasty (UPI) and Its Peers - November 28 at 3:31 AM
Uroplasty (UPI) & Its Peers Head-To-Head ComparisonUroplasty (UPI) & Its Peers Head-To-Head Comparison - November 27 at 9:36 AM
Head-To-Head Contrast: Uroplasty (UPI) vs. Its RivalsHead-To-Head Contrast: Uroplasty (UPI) vs. Its Rivals - November 25 at 11:04 PM
Uroplasty (UPI) & Its Peers Head to Head AnalysisUroplasty (UPI) & Its Peers Head to Head Analysis - November 25 at 5:10 AM
Head-To-Head Analysis: Uroplasty (UPI) vs. The CompetitionHead-To-Head Analysis: Uroplasty (UPI) vs. The Competition - November 24 at 11:16 PM
Uroplasty (UPI) vs. Its Peers Head to Head ReviewUroplasty (UPI) vs. Its Peers Head to Head Review - November 23 at 9:16 PM
Contrasting Uroplasty (UPI) & Its RivalsContrasting Uroplasty (UPI) & Its Rivals - November 22 at 11:10 PM
Uroplasty (UPI) & Its Rivals Head to Head ComparisonUroplasty (UPI) & Its Rivals Head to Head Comparison - November 21 at 7:43 AM
Uroplasty (UPI) vs. The Competition Financial AnalysisUroplasty (UPI) vs. The Competition Financial Analysis - November 18 at 5:20 PM
Analyzing Uroplasty (UPI) and Second Sight Medical Products (EYES)Analyzing Uroplasty (UPI) and Second Sight Medical Products (EYES) - November 16 at 10:28 AM
Uroplasty (UPI) vs. The Competition Head-To-Head SurveyUroplasty (UPI) vs. The Competition Head-To-Head Survey - November 14 at 9:22 PM
Uroplasty (UPI) versus Its Rivals Financial AnalysisUroplasty (UPI) versus Its Rivals Financial Analysis - November 14 at 7:18 PM

SEC Filings

Uroplasty (NASDAQ:UPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Uroplasty (NASDAQ:UPI) Income Statement, Balance Sheet and Cash Flow Statement


Uroplasty (NASDAQ UPI) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.